JP2023514224A5 - - Google Patents
Info
- Publication number
- JP2023514224A5 JP2023514224A5 JP2022548786A JP2022548786A JP2023514224A5 JP 2023514224 A5 JP2023514224 A5 JP 2023514224A5 JP 2022548786 A JP2022548786 A JP 2022548786A JP 2022548786 A JP2022548786 A JP 2022548786A JP 2023514224 A5 JP2023514224 A5 JP 2023514224A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- treatment
- antibody
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062975663P | 2020-02-12 | 2020-02-12 | |
| US62/975,663 | 2020-02-12 | ||
| PCT/US2021/017665 WO2021163329A1 (en) | 2020-02-12 | 2021-02-11 | Anti-bcma therapy in autoimmune disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023514224A JP2023514224A (ja) | 2023-04-05 |
| JP2023514224A5 true JP2023514224A5 (enExample) | 2025-09-25 |
| JP7783183B2 JP7783183B2 (ja) | 2025-12-09 |
Family
ID=77291870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548786A Active JP7783183B2 (ja) | 2020-02-12 | 2021-02-11 | 自己免疫障害における抗ｂｃｍａ治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240052064A1 (enExample) |
| EP (1) | EP4103224A4 (enExample) |
| JP (1) | JP7783183B2 (enExample) |
| KR (1) | KR20220141306A (enExample) |
| CN (1) | CN115551539A (enExample) |
| AU (1) | AU2021221123A1 (enExample) |
| BR (1) | BR112022014646A2 (enExample) |
| CA (1) | CA3169696A1 (enExample) |
| IL (1) | IL295471A (enExample) |
| MX (1) | MX2022009784A (enExample) |
| WO (1) | WO2021163329A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2963692A1 (en) | 2014-10-09 | 2016-04-14 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 |
| WO2023044633A1 (zh) * | 2021-09-22 | 2023-03-30 | 南京驯鹿医疗技术有限公司 | Bcma car-t在制备用于治疗自身免疫病的药物中的应用 |
| WO2026033437A1 (en) * | 2024-08-07 | 2026-02-12 | Janssen Biotech, Inc. | Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics |
| WO2026037514A1 (en) * | 2024-08-13 | 2026-02-19 | Friedrich-Alexander-Universität Erlangen-Nürnberg, in Vertretung des Freistaates Bayern | A bispecific binding agent targeting cd3 and bcma for the treatment of autoimmune diseases |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016302881B2 (en) * | 2015-08-03 | 2022-09-15 | Bristol-Myers Squibb Company | Monoclonal antibodies against BCMA |
| JP2020524512A (ja) * | 2017-06-21 | 2020-08-20 | アイセル・ジーン・セラピューティクス・エルエルシー | キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法 |
| CA3080904A1 (en) * | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for b-cell maturation antigen |
-
2021
- 2021-02-11 IL IL295471A patent/IL295471A/en unknown
- 2021-02-11 AU AU2021221123A patent/AU2021221123A1/en active Pending
- 2021-02-11 CN CN202180027778.XA patent/CN115551539A/zh active Pending
- 2021-02-11 KR KR1020227030166A patent/KR20220141306A/ko active Pending
- 2021-02-11 CA CA3169696A patent/CA3169696A1/en active Pending
- 2021-02-11 JP JP2022548786A patent/JP7783183B2/ja active Active
- 2021-02-11 US US17/798,983 patent/US20240052064A1/en active Pending
- 2021-02-11 WO PCT/US2021/017665 patent/WO2021163329A1/en not_active Ceased
- 2021-02-11 BR BR112022014646A patent/BR112022014646A2/pt unknown
- 2021-02-11 EP EP21754567.2A patent/EP4103224A4/en active Pending
- 2021-02-11 MX MX2022009784A patent/MX2022009784A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6278224B2 (ja) | Ｐｄ−１アゴニストからなる自己免疫疾患治療剤 | |
| JP2020520665A5 (enExample) | ||
| JP2020507605A5 (enExample) | ||
| US11352428B2 (en) | Modulation of immune response using BTLA agonist antibodies | |
| JP2020522513A5 (enExample) | ||
| RS55995B2 (sr) | Prevencija neželjenih efekata uzrokovanih cd3-specifičnim vezujućim domenima | |
| JP7783183B2 (ja) | 自己免疫障害における抗ｂｃｍａ治療 | |
| JP2018537418A5 (enExample) | ||
| JP2023532129A5 (enExample) | ||
| JPH06501931A (ja) | 抗接着性抗体を用いるエンドトキシンショックの治療法 | |
| WO2013140787A1 (ja) | 特発性炎症性筋疾患の予防又は治療剤 | |
| JP2026016543A5 (enExample) | ||
| Dariushnejad et al. | Rheumatoid arthritis: current therapeutics compendium | |
| JP2019526244A5 (enExample) | ||
| Alawadhi et al. | The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what’s in it for African and Middle Eastern rheumatologists | |
| CN115746144A (zh) | 抗tigit-pd1双特异性抗体及其应用 | |
| Michalova et al. | Biologic agents in the management of inflammatory eye diseases | |
| JP3914342B2 (ja) | ｇｐ３４結合阻害物を有効成分として含有する医薬組成物 | |
| JP2025503533A5 (enExample) | ||
| JP2023540618A5 (enExample) | ||
| Hatekar et al. | An Unusual Case of Neurofascin 186 Neuropathy | |
| CN118108845B (zh) | 一种靶向B7-H3的CAR-γδT细胞的制备方法及应用 | |
| CN120518768B (zh) | 抗lag-3的单克隆抗体、抗pd-1与lag-3的双特异性抗体、制备方法及其应用 | |
| WO2025007943A1 (zh) | 用taci-fc融合蛋白治疗anca相关性血管炎的方法 | |
| TW202540166A (zh) | 用於治療自體免疫性疾病／自體免疫性病症的ｃｄ１９選擇性ｔ細胞接合分子 |